Importance Patients with cancer have an increased risk of severe disease and mortality from
COVID-19, as the disease and antineoplastic therapy cause reduced vaccine …

Background Patients receiving hematopoietic stem cell transplantation (HSCT) or chimeric
antigen receptor T cell (CAR T-cell) therapy are immunocompromised and at high risk of …

Chimeric antigen receptor T (CAR T) cell and bispecific antibody therapies have shown
unprecedented efficacy in heavily pretreated patients with multiple myeloma (MM). However …

Recipients after hematopoietic stem cell transplantation (HSCT) or chimeric antigen receptor
T-cell (CAR-T) therapy are at increased risk for unfavorable outcomes after SARS-CoV-2 …

Background The outcome of COVID-19 in allogeneic hematopoietic stem cell transplantation
(HSCT) recipients is almost uniformely considered poor. The aim of present study was to …

There is a paucity of granular data on infection risk with B-cell maturation antigen (BMCA)
and GPRC5D bispecific antibodies (bsAb) in relapsed/refractory multiple myeloma (RRMM) …

Patients with hematologic malignancies (HM) have demonstrated impaired immune
responses following SARS-CoV-2 vaccination. Factors associated with poor immunogenicity …

The efficacy of SARS-CoV-2 vaccination in patients with hematological malignancies (HM)
appears limited due to disease and treatment-associated immune impairment. We …

Patients with cancer demonstrate an increased vulnerability for infection and severe disease
by SARS-CoV-2, the causative agent of COVID-19. Risk factors for severe COVID-19 include …

Simple Summary Taking into consideration the high risk of patients with cancer for severe
COVID-19 infection, prioritization has been given to primary prevention with both primary …